Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug

While the company remains optimistic about the drug's potential, questions remain as to whether Santaris has the intellectual property necessary to bring it to market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.